Corona Remedies Ltd
P&L
Quarterly Consolidated
vs Q2 FY26
Corona Remedies Ltd Reports 15.0% Revenue Growth in Q3FY26
02 Feb 2026 · 2 Feb, 6:44 pm
Summary
Corona Remedies Ltd, a branded pharmaceutical formulation company, has reported a revenue growth of 15.0% in Q3FY26. The revenue for the nine months ended December 31, 2025, stood at ₹ 1,050.09 Cr, with a Profit After Tax (PAT) of ₹ 154.08 Cr. The PAT for the quarter grew by 23.7% on a Y-o-Y basis.
Key Highlights
- 1
Revenue from Operations for Q3FY26 stood at ₹ 342.42 Cr
- 2
Revenue grew by 15.0% on Y-o-Y basis for Q3FY26
- 3
PAT for Q3FY26 was ₹ 55.56 Cr
- 4
PAT of the above periods grew by 23.7% on Y-o-Y basis for Q3FY26
- 5
RoE for Nine Months FY26 was 31.1%
- 6
ROCE for Nine Months FY26 was 48.0%
- 7
OCF to EBITDA for Nine Months FY26 was 86.3%
- 8
Net Working Capital Days for Nine Months FY26 was 18 Days
- 9
Company has consistently delivered on its guided revenue and PAT growth
Management Comments
Mr. Nirav K. Mehta
We are delighted to report a strong financial performance in Q3 and 9MFY26... Our revenues & PAT has grown as per our aspiration in the last 3 quarters and are optimistic of maintaining similar trajectory going forward... Our strong performance reflects the consistency of our strategy, disciplined execution and deep focus on our core therapeutic segments... By strengthening our field force, expanding our brand portfolio and maintaining a sharp focus on specialists’ prescriptions, we have continued to outperform the market while building a sustainable platform for long-term growth.
Informational and educational content only. Not investment advice.